Cervical Cancer Chemotherapy: — Cisplatin and Chemoradiation Regimens

Not everyone. Early-stage cervical cancer — such as stage IA1 and some IA2 and IB1 tumours — is often treated with surgery alone, without chemotherapy. Chemotherapy becomes part of the treatment plan for locally advanced disease, and it is used systemically for recurrent or metastatic disease. Whether you need it, and in what form, depends on the stage at diagnosis, the size and position of the tumour, and your overall fitness. Your oncologist will explain which applies to your situation.

Cisplatin acts as a radiosensitiser — it makes cancer cells more vulnerable to radiation damage. When both are given at the same time, the radiation is more effective than it would be alone. This is why, for locally advanced cervical cancer, the two treatments are run concurrently rather than in sequence. Giving cisplatin alone, without radiation, is not the standard approach in this setting; its role here is specifically to enhance what the radiation does.

The concurrent chemoradiation phase runs across the weeks of external beam radiotherapy, with cisplatin given once a week during that time. Brachytherapy follows after this phase completes. Your radiation oncologist will give you a specific schedule at the start of treatment and explain the total expected duration for your plan. The schedule varies between patients, and your team will tell you what to expect in your individual case.

Carboplatin is the most commonly used alternative when cisplatin is not suitable. Both drugs belong to the platinum family and work in a similar way, but carboplatin is less likely to cause kidney damage and carries a lower risk of hearing problems. It is combined with paclitaxel in the systemic regimens for recurrent and metastatic disease. The decision to use carboplatin instead of cisplatin is based on your kidney function, existing hearing test results, and treatment history — your oncologist will assess this and explain the choice.

Pembrolizumab, an immunotherapy drug that targets the PD-1 pathway, has been incorporated into systemic treatment for recurrent or metastatic cervical cancer in patients whose tumours test positive for PD-L1. This addition to the chemotherapy backbone is addressed in current NCCN, ASCO, and ESMO guidance for eligible patients. Whether pembrolizumab applies to you depends on your tumour biology, prior treatment, and overall fitness — your oncologist will assess this alongside any biomarker testing done on your tumour.

It depends on which drugs are part of your regimen. Paclitaxel, which is used in the systemic regimens for recurrent or metastatic disease, typically causes significant hair loss. Cisplatin alone, as given during concurrent chemoradiation, causes less hair loss than paclitaxel but may cause some thinning. When both are used together, significant hair loss is expected. Hair usually grows back after treatment ends, though the timing varies. Your oncology nurse or pharmacist can explain what to expect based on your specific regimen.